Biocept Story

BIOC -- USA Stock

USD 4.14 0.22 5.05%

Macroaxis Story

40% of stocks are less volatile than Biocept, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. As many adventurous traders are excited about healthcare space, it is only fair to go over the risk of shorting Biocept based on its current volatility spike. We will go over a few points Biocept investors should remember regarding its volatility.

Published over two weeks ago

View all stories for Biocept | View All Stories

Will Biocept (NASDAQ:BIOC) current volatility spike continue?

The company conducts business under Healthcare sector and is part of Diagnostics & Research industry.

Volatility is a rate at which the price of Biocept or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Biocept may increase or decrease. In other words, similar to Biocept's beta indicator, it measures the risk of Biocept and helps estimate the fluctuations that may happen in a short period of time. So if prices of Biocept fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.

Please read more on our technical analysis page.

How important is Biocept's Liquidity

Biocept financial leverage refers to using borrowed capital as a funding source to finance Biocept ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Biocept financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Biocept's total debt and its cash.

How Biocept utilizes its cash?

To perform a cash flow analysis of Biocept, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biocept is receiving and how much cash it distributes out in a given period. The Biocept cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Biocept Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (19.79 Million)

Biocept Volatility Drivers

Biocept unsystematic risk is unique to Biocept and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Biocept you can also buy Emmaus Life Sciences. You can also mitigate this risk by investing in the diagnostics & research sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Biocept important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Biocept income statement and balance sheet. Here are more details about Biocept volatility.

	Total Assets	Current Assets	Cash and Equivalents	Total Debt	Debt Current	Shareholders Equity	Total Liabilities	Current Liabilities	Consolidated Income	Cost of Revenue	Gross Profit	Interest Expense	Net Income	Net Income Common Stock	Operating Expenses	Operating Income	Weighted Average Shares	Income Tax Expense	Capital Expenditure	Share Based Compensation	Asset Turnover	Book Value per Share	Current Ratio	Debt to Equity Ratio	EBITDA Margin	Earnings per Basic Share	Free Cash Flow per Share	Gross Margin	Profit Margin	Price to Book Value	Price to Earnings Ratio	Price to Sales Ratio	Return on Average Assets	Return on Average Equity	Return on Sales	Sales per Share	Average Assets	Earnings before Tax	Average Equity	Enterprise Value	Free Cash Flow	Invested Capital	Invested Capital Average	Market Capitalization	Tangible Asset Value	Working Capital
Total Assets		1.0	0.93	-0.01	-0.46	0.87	0.42	-0.09	-0.33	0.95	0.73	-0.63	-0.33	-0.33	0.77	-0.23	0.98	0.13	-0.53	0.18	0.86	0.48	0.47	0.13	0.58	0.48	0.46	0.63	0.62	0.47	-0.9	-0.6	0.65	-0.11	0.32	-0.37	0.97	-0.34	0.82	0.88	-0.61	0.99	0.95	0.92	1.0	0.83
Current Assets	1.0		0.96	-0.05	-0.5	0.89	0.37	-0.13	-0.35	0.94	0.7	-0.65	-0.35	-0.34	0.76	-0.25	0.97	0.11	-0.52	0.23	0.84	0.52	0.53	0.1	0.61	0.52	0.5	0.64	0.64	0.49	-0.89	-0.6	0.69	-0.11	0.35	-0.39	0.98	-0.35	0.84	0.87	-0.62	0.98	0.96	0.91	1.0	0.86
Cash and Equivalents	0.93	0.96		-0.2	-0.62	0.92	0.17	-0.32	-0.45	0.87	0.54	-0.71	-0.45	-0.43	0.74	-0.35	0.85	0.09	-0.47	0.39	0.74	0.65	0.71	0.04	0.69	0.64	0.62	0.66	0.72	0.57	-0.79	-0.63	0.81	-0.1	0.43	-0.48	0.96	-0.45	0.91	0.79	-0.68	0.9	0.96	0.82	0.93	0.92
Total Debt	-0.01	-0.05	-0.2		0.86	-0.49	0.88	0.94	0.65	-0.21	0.54	0.58	0.65	0.65	-0.29	0.69	0.14	-0.43	0.31	-0.66	-0.14	-0.84	-0.48	-0.01	-0.74	-0.71	-0.68	-0.39	-0.65	-0.6	-0.22	0.56	-0.63	0.08	-0.42	0.43	-0.17	0.65	-0.49	0.13	0.57	0.02	-0.18	0.15	-0.01	-0.53
Debt Current	-0.46	-0.5	-0.62	0.86		-0.83	0.59	0.91	0.65	-0.58	0.08	0.75	0.65	0.64	-0.59	0.64	-0.33	-0.41	0.5	-0.74	-0.49	-0.97	-0.73	0.07	-0.9	-0.83	-0.8	-0.56	-0.84	-0.69	0.26	0.69	-0.87	0.12	-0.48	0.6	-0.59	0.65	-0.81	-0.32	0.74	-0.46	-0.62	-0.32	-0.46	-0.87
Shareholders Equity	0.87	0.89	0.92	-0.49	-0.83		-0.09	-0.56	-0.63	0.91	0.37	-0.85	-0.63	-0.62	0.83	-0.56	0.77	0.32	-0.63	0.49	0.8	0.83	0.69	0.1	0.87	0.76	0.73	0.75	0.87	0.71	-0.67	-0.79	0.9	-0.13	0.46	-0.59	0.93	-0.63	0.96	0.7	-0.83	0.85	0.93	0.72	0.87	0.99
Total Liabilities	0.42	0.37	0.17	0.88	0.59	-0.09		0.84	0.48	0.24	0.8	0.29	0.48	0.48	0.01	0.56	0.56	-0.32	0.08	-0.53	0.26	-0.56	-0.31	0.08	-0.42	-0.43	-0.4	-0.1	-0.34	-0.36	-0.57	0.25	-0.33	0.01	-0.2	0.33	0.25	0.48	-0.13	0.49	0.29	0.43	0.21	0.53	0.42	-0.15
Current Liabilities	-0.09	-0.13	-0.32	0.94	0.91	-0.56	0.84		0.61	-0.22	0.4	0.58	0.61	0.61	-0.35	0.64	0.07	-0.39	0.35	-0.76	-0.15	-0.87	-0.66	0.15	-0.74	-0.71	-0.67	-0.36	-0.68	-0.58	-0.09	0.5	-0.72	0.06	-0.35	0.6	-0.25	0.61	-0.57	0.01	0.58	-0.1	-0.3	0.03	-0.09	-0.63
Consolidated Income	-0.33	-0.35	-0.45	0.65	0.65	-0.63	0.48	0.61		-0.55	0.32	0.86	1.0	1.0	-0.78	0.99	-0.19	-0.49	0.55	-0.25	-0.45	-0.69	-0.43	-0.23	-0.75	-0.66	-0.63	-0.79	-0.84	-0.76	-0.01	0.85	-0.73	0.2	-0.37	0.64	-0.47	1.0	-0.69	-0.05	0.94	-0.29	-0.52	-0.07	-0.33	-0.6
Cost of Revenue	0.95	0.94	0.87	-0.21	-0.58	0.91	0.24	-0.22	-0.55		0.53	-0.79	-0.55	-0.54	0.85	-0.46	0.9	0.33	-0.64	0.24	0.93	0.62	0.43	0.27	0.75	0.63	0.62	0.81	0.79	0.66	-0.77	-0.8	0.74	-0.11	0.46	-0.38	0.95	-0.55	0.87	0.79	-0.77	0.92	0.94	0.82	0.95	0.85
Gross Profit	0.73	0.7	0.54	0.54	0.08	0.37	0.8	0.4	0.32	0.53		-0.02	0.32	0.33	0.31	0.42	0.83	-0.14	-0.26	-0.14	0.55	-0.12	0.08	-0.05	-0.05	-0.14	-0.14	0.05	0.01	-0.12	-0.87	0.02	0.07	0.02	-0.15	-0.08	0.59	0.32	0.27	0.82	0.0	0.78	0.58	0.84	0.73	0.33
Interest Expense	-0.63	-0.65	-0.71	0.58	0.75	-0.85	0.29	0.58	0.86	-0.79	-0.02		0.86	0.85	-0.88	0.84	-0.5	-0.48	0.62	-0.35	-0.74	-0.79	-0.45	-0.46	-0.86	-0.74	-0.7	-0.92	-0.92	-0.93	0.38	0.97	-0.83	0.01	-0.41	0.64	-0.73	0.86	-0.85	-0.47	0.92	-0.59	-0.75	-0.46	-0.63	-0.82
Net Income	-0.33	-0.35	-0.45	0.65	0.65	-0.63	0.48	0.61	1.0	-0.55	0.32	0.86		1.0	-0.78	0.99	-0.19	-0.49	0.55	-0.25	-0.45	-0.69	-0.43	-0.23	-0.75	-0.66	-0.63	-0.79	-0.84	-0.76	-0.01	0.85	-0.73	0.2	-0.37	0.64	-0.47	1.0	-0.69	-0.05	0.94	-0.29	-0.52	-0.07	-0.33	-0.6
Net Income Common Stock	-0.33	-0.34	-0.43	0.65	0.64	-0.62	0.48	0.61	1.0	-0.54	0.33	0.85	1.0		-0.77	0.99	-0.18	-0.48	0.53	-0.24	-0.44	-0.68	-0.42	-0.23	-0.74	-0.66	-0.62	-0.79	-0.83	-0.75	-0.03	0.84	-0.72	0.21	-0.36	0.63	-0.46	1.0	-0.68	-0.03	0.94	-0.28	-0.5	-0.05	-0.33	-0.59
Operating Expenses	0.77	0.76	0.74	-0.29	-0.59	0.83	0.01	-0.35	-0.78	0.85	0.31	-0.88	-0.78	-0.77		-0.72	0.69	0.44	-0.72	0.14	0.79	0.6	0.44	0.25	0.7	0.54	0.5	0.83	0.84	0.71	-0.53	-0.84	0.75	-0.15	0.22	-0.72	0.81	-0.78	0.83	0.57	-0.92	0.77	0.85	0.59	0.77	0.79
Operating Income	-0.23	-0.25	-0.35	0.69	0.64	-0.56	0.56	0.64	0.99	-0.46	0.42	0.84	0.99	0.99	-0.72		-0.08	-0.52	0.5	-0.26	-0.38	-0.68	-0.36	-0.28	-0.73	-0.65	-0.61	-0.77	-0.81	-0.78	-0.1	0.84	-0.68	0.16	-0.35	0.62	-0.37	0.99	-0.62	0.03	0.9	-0.19	-0.42	0.02	-0.23	-0.53
Weighted Average Shares	0.98	0.97	0.85	0.14	-0.33	0.77	0.56	0.07	-0.19	0.9	0.83	-0.5	-0.19	-0.18	0.69	-0.08		0.07	-0.48	0.07	0.84	0.33	0.35	0.11	0.45	0.34	0.33	0.52	0.49	0.33	-0.92	-0.48	0.51	-0.1	0.23	-0.27	0.91	-0.19	0.7	0.89	-0.48	0.98	0.89	0.94	0.98	0.72
Income Tax Expense	0.13	0.11	0.09	-0.43	-0.41	0.32	-0.32	-0.39	-0.49	0.33	-0.14	-0.48	-0.49	-0.48	0.44	-0.52	0.07		-0.83	0.35	0.37	0.46	0.08	0.23	0.52	0.46	0.44	0.53	0.55	0.59	-0.12	-0.54	0.46	-0.19	0.31	-0.27	0.25	-0.49	0.39	0.24	-0.52	0.15	0.25	0.19	0.13	0.29
Capital Expenditure	-0.53	-0.52	-0.47	0.31	0.5	-0.63	0.08	0.35	0.55	-0.64	-0.26	0.62	0.55	0.53	-0.72	0.5	-0.48	-0.83		-0.31	-0.66	-0.51	-0.28	-0.17	-0.6	-0.45	-0.42	-0.63	-0.68	-0.59	0.44	0.64	-0.6	0.14	-0.2	0.5	-0.6	0.55	-0.63	-0.55	0.69	-0.56	-0.61	-0.51	-0.53	-0.59
Share Based Compensation	0.18	0.23	0.39	-0.66	-0.74	0.49	-0.53	-0.76	-0.25	0.24	-0.14	-0.35	-0.25	-0.24	0.14	-0.26	0.07	0.35	-0.31		0.24	0.8	0.73	-0.27	0.7	0.79	0.78	0.31	0.6	0.48	-0.14	-0.35	0.68	0.17	0.66	-0.19	0.3	-0.25	0.56	0.26	-0.31	0.2	0.36	0.19	0.18	0.58
Asset Turnover	0.86	0.84	0.74	-0.14	-0.49	0.8	0.26	-0.15	-0.45	0.93	0.55	-0.74	-0.45	-0.44	0.79	-0.38	0.84	0.37	-0.66	0.24		0.53	0.24	0.42	0.69	0.53	0.52	0.8	0.74	0.68	-0.71	-0.79	0.59	0.22	0.37	-0.33	0.81	-0.45	0.73	0.81	-0.66	0.85	0.84	0.78	0.86	0.74
Book Value per Share	0.48	0.52	0.65	-0.84	-0.97	0.83	-0.56	-0.87	-0.69	0.62	-0.12	-0.79	-0.69	-0.68	0.6	-0.68	0.33	0.46	-0.51	0.8	0.53		0.75	0.0	0.96	0.94	0.91	0.67	0.9	0.77	-0.27	-0.76	0.92	-0.07	0.65	-0.5	0.62	-0.69	0.86	0.35	-0.76	0.46	0.65	0.34	0.48	0.87
Current Ratio	0.47	0.53	0.71	-0.48	-0.73	0.69	-0.31	-0.66	-0.43	0.43	0.08	-0.45	-0.43	-0.42	0.44	-0.36	0.35	0.08	-0.28	0.73	0.24	0.75		-0.5	0.65	0.73	0.7	0.33	0.64	0.36	-0.34	-0.35	0.84	-0.23	0.5	-0.5	0.6	-0.43	0.77	0.33	-0.55	0.48	0.65	0.35	0.47	0.77
Debt to Equity Ratio	0.13	0.1	0.04	-0.01	0.07	0.1	0.08	0.15	-0.23	0.27	-0.05	-0.46	-0.23	-0.23	0.25	-0.28	0.11	0.23	-0.17	-0.27	0.42	0.0	-0.5		0.14	0.02	0.02	0.53	0.18	0.56	-0.09	-0.52	-0.05	0.41	0.01	0.03	0.08	-0.23	0.02	0.2	-0.18	0.06	0.06	0.15	0.13	0.0
EBITDA Margin	0.58	0.61	0.69	-0.74	-0.9	0.87	-0.42	-0.74	-0.75	0.75	-0.05	-0.86	-0.75	-0.74	0.7	-0.73	0.45	0.52	-0.6	0.7	0.69	0.96	0.65	0.14		0.95	0.93	0.82	0.96	0.85	-0.34	-0.88	0.92	-0.02	0.72	-0.43	0.69	-0.75	0.89	0.43	-0.83	0.55	0.72	0.42	0.58	0.87
Earnings per Basic Share	0.48	0.52	0.64	-0.71	-0.83	0.76	-0.43	-0.71	-0.66	0.63	-0.14	-0.74	-0.66	-0.66	0.54	-0.65	0.34	0.46	-0.45	0.79	0.53	0.94	0.73	0.02	0.95		1.0	0.74	0.89	0.77	-0.27	-0.76	0.91	-0.07	0.86	-0.28	0.62	-0.66	0.85	0.35	-0.72	0.43	0.64	0.34	0.48	0.78
Free Cash Flow per Share	0.46	0.5	0.62	-0.68	-0.8	0.73	-0.4	-0.67	-0.63	0.62	-0.14	-0.7	-0.63	-0.62	0.5	-0.61	0.33	0.44	-0.42	0.78	0.52	0.91	0.7	0.02	0.93	1.0		0.73	0.86	0.75	-0.26	-0.74	0.88	-0.07	0.9	-0.2	0.6	-0.63	0.82	0.34	-0.68	0.41	0.62	0.33	0.46	0.75
Gross Margin	0.63	0.64	0.66	-0.39	-0.56	0.75	-0.1	-0.36	-0.79	0.81	0.05	-0.92	-0.79	-0.79	0.83	-0.77	0.52	0.53	-0.63	0.31	0.8	0.67	0.33	0.53	0.82	0.74	0.73		0.9	0.92	-0.39	-0.97	0.75	0.08	0.57	-0.4	0.7	-0.79	0.79	0.5	-0.85	0.58	0.73	0.48	0.63	0.69
Profit Margin	0.62	0.64	0.72	-0.65	-0.84	0.87	-0.34	-0.68	-0.84	0.79	0.01	-0.92	-0.84	-0.83	0.84	-0.81	0.49	0.55	-0.68	0.6	0.74	0.9	0.64	0.18	0.96	0.89	0.86	0.9		0.88	-0.36	-0.93	0.93	-0.01	0.61	-0.58	0.73	-0.84	0.91	0.46	-0.92	0.6	0.79	0.45	0.62	0.86
Price to Book Value	0.47	0.49	0.57	-0.6	-0.69	0.71	-0.36	-0.58	-0.76	0.66	-0.12	-0.93	-0.76	-0.75	0.71	-0.78	0.33	0.59	-0.59	0.48	0.68	0.77	0.36	0.56	0.85	0.77	0.75	0.92	0.88		-0.28	-0.94	0.77	0.17	0.53	-0.47	0.57	-0.76	0.74	0.43	-0.79	0.43	0.61	0.38	0.47	0.69
Price to Earnings Ratio	-0.9	-0.89	-0.79	-0.22	0.26	-0.67	-0.57	-0.09	-0.01	-0.77	-0.87	0.38	-0.01	-0.03	-0.53	-0.1	-0.92	-0.12	0.44	-0.14	-0.71	-0.27	-0.34	-0.09	-0.34	-0.27	-0.26	-0.39	-0.36	-0.28		0.32	-0.47	0.12	-0.18	0.22	-0.85	-0.01	-0.63	-0.96	0.31	-0.92	-0.81	-0.99	-0.9	-0.65
Price to Sales Ratio	-0.6	-0.6	-0.63	0.56	0.69	-0.79	0.25	0.5	0.85	-0.8	0.02	0.97	0.85	0.84	-0.84	0.84	-0.48	-0.54	0.64	-0.35	-0.79	-0.76	-0.35	-0.52	-0.88	-0.76	-0.74	-0.97	-0.93	-0.94	0.32		-0.77	-0.08	-0.52	0.49	-0.67	0.85	-0.8	-0.43	0.89	-0.55	-0.7	-0.42	-0.6	-0.74
Return on Average Assets	0.65	0.69	0.81	-0.63	-0.87	0.9	-0.33	-0.72	-0.73	0.74	0.07	-0.83	-0.73	-0.72	0.75	-0.68	0.51	0.46	-0.6	0.68	0.59	0.92	0.84	-0.05	0.92	0.91	0.88	0.75	0.93	0.77	-0.47	-0.77		-0.22	0.63	-0.59	0.8	-0.73	0.97	0.51	-0.85	0.64	0.82	0.52	0.65	0.92
Return on Average Equity	-0.11	-0.11	-0.1	0.08	0.12	-0.13	0.01	0.06	0.2	-0.11	0.02	0.01	0.2	0.21	-0.15	0.16	-0.1	-0.19	0.14	0.17	0.22	-0.07	-0.23	0.41	-0.02	-0.07	-0.07	0.08	-0.01	0.17	0.12	-0.08	-0.22		-0.05	0.13	-0.24	0.2	-0.21	0.09	0.24	-0.1	-0.12	-0.06	-0.11	-0.12
Return on Sales	0.32	0.35	0.43	-0.42	-0.48	0.46	-0.2	-0.35	-0.37	0.46	-0.15	-0.41	-0.37	-0.36	0.22	-0.35	0.23	0.31	-0.2	0.66	0.37	0.65	0.5	0.01	0.72	0.86	0.9	0.57	0.61	0.53	-0.18	-0.52	0.63	-0.05		0.23	0.42	-0.37	0.58	0.24	-0.39	0.24	0.41	0.23	0.32	0.46
Sales per Share	-0.37	-0.39	-0.48	0.43	0.6	-0.59	0.33	0.6	0.64	-0.38	-0.08	0.64	0.64	0.63	-0.72	0.62	-0.27	-0.27	0.5	-0.19	-0.33	-0.5	-0.5	0.03	-0.43	-0.28	-0.2	-0.4	-0.58	-0.47	0.22	0.49	-0.59	0.13	0.23		-0.46	0.64	-0.57	-0.24	0.7	-0.43	-0.53	-0.25	-0.37	-0.62
Average Assets	0.97	0.98	0.96	-0.17	-0.59	0.93	0.25	-0.25	-0.47	0.95	0.59	-0.73	-0.47	-0.46	0.81	-0.37	0.91	0.25	-0.6	0.3	0.81	0.62	0.6	0.08	0.69	0.62	0.6	0.7	0.73	0.57	-0.85	-0.67	0.8	-0.24	0.42	-0.46		-0.47	0.92	0.83	-0.73	0.95	0.98	0.88	0.97	0.9
Earnings before Tax	-0.34	-0.35	-0.45	0.65	0.65	-0.63	0.48	0.61	1.0	-0.55	0.32	0.86	1.0	1.0	-0.78	0.99	-0.19	-0.49	0.55	-0.25	-0.45	-0.69	-0.43	-0.23	-0.75	-0.66	-0.63	-0.79	-0.84	-0.76	-0.01	0.85	-0.73	0.2	-0.37	0.64	-0.47		-0.69	-0.05	0.94	-0.29	-0.52	-0.07	-0.34	-0.6
Average Equity	0.82	0.84	0.91	-0.49	-0.81	0.96	-0.13	-0.57	-0.69	0.87	0.27	-0.85	-0.69	-0.68	0.83	-0.62	0.7	0.39	-0.63	0.56	0.73	0.86	0.77	0.02	0.89	0.85	0.82	0.79	0.91	0.74	-0.63	-0.8	0.97	-0.21	0.58	-0.57	0.92	-0.69		0.65	-0.86	0.79	0.93	0.68	0.82	0.96
Enterprise Value	0.88	0.87	0.79	0.13	-0.32	0.7	0.49	0.01	-0.05	0.79	0.82	-0.47	-0.05	-0.03	0.57	0.03	0.89	0.24	-0.55	0.26	0.81	0.35	0.33	0.2	0.43	0.35	0.34	0.5	0.46	0.43	-0.96	-0.43	0.51	0.09	0.24	-0.24	0.83	-0.05	0.65		-0.35	0.91	0.83	0.98	0.88	0.68
Free Cash Flow	-0.61	-0.62	-0.68	0.57	0.74	-0.83	0.29	0.58	0.94	-0.77	0.0	0.92	0.94	0.94	-0.92	0.9	-0.48	-0.52	0.69	-0.31	-0.66	-0.76	-0.55	-0.18	-0.83	-0.72	-0.68	-0.85	-0.92	-0.79	0.31	0.89	-0.85	0.24	-0.39	0.7	-0.73	0.94	-0.86	-0.35		-0.59	-0.76	-0.38	-0.61	-0.8
Invested Capital	0.99	0.98	0.9	0.02	-0.46	0.85	0.43	-0.1	-0.29	0.92	0.78	-0.59	-0.29	-0.28	0.77	-0.19	0.98	0.15	-0.56	0.2	0.85	0.46	0.48	0.06	0.55	0.43	0.41	0.58	0.6	0.43	-0.92	-0.55	0.64	-0.1	0.24	-0.43	0.95	-0.29	0.79	0.91	-0.59		0.95	0.94	0.99	0.82
Invested Capital Average	0.95	0.96	0.96	-0.18	-0.62	0.93	0.21	-0.3	-0.52	0.94	0.58	-0.75	-0.52	-0.5	0.85	-0.42	0.89	0.25	-0.61	0.36	0.84	0.65	0.65	0.06	0.72	0.64	0.62	0.73	0.79	0.61	-0.81	-0.7	0.82	-0.12	0.41	-0.53	0.98	-0.52	0.93	0.83	-0.76	0.95		0.85	0.95	0.91
Market Capitalization	0.92	0.91	0.82	0.15	-0.32	0.72	0.53	0.03	-0.07	0.82	0.84	-0.46	-0.07	-0.05	0.59	0.02	0.94	0.19	-0.51	0.19	0.78	0.34	0.35	0.15	0.42	0.34	0.33	0.48	0.45	0.38	-0.99	-0.42	0.52	-0.06	0.23	-0.25	0.88	-0.07	0.68	0.98	-0.38	0.94	0.85		0.92	0.69
Tangible Asset Value	1.0	1.0	0.93	-0.01	-0.46	0.87	0.42	-0.09	-0.33	0.95	0.73	-0.63	-0.33	-0.33	0.77	-0.23	0.98	0.13	-0.53	0.18	0.86	0.48	0.47	0.13	0.58	0.48	0.46	0.63	0.62	0.47	-0.9	-0.6	0.65	-0.11	0.32	-0.37	0.97	-0.34	0.82	0.88	-0.61	0.99	0.95	0.92		0.83
Working Capital	0.83	0.86	0.92	-0.53	-0.87	0.99	-0.15	-0.63	-0.6	0.85	0.33	-0.82	-0.6	-0.59	0.79	-0.53	0.72	0.29	-0.59	0.58	0.74	0.87	0.77	0.0	0.87	0.78	0.75	0.69	0.86	0.69	-0.65	-0.74	0.92	-0.12	0.46	-0.62	0.9	-0.6	0.96	0.68	-0.8	0.82	0.91	0.69	0.83

Click cells to compare fundamentals

Acquisition by David Hale of 500 shares of Biocept subject to Rule 16b-3

Legal trades by Biocept insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Biocept insider trading alert for grant of employee stock option (right to buy) by David Hale, the corporate stakeholder, on 23rd of December 2020. This event was filed by Biocept Inc with SEC on 2019-06-19. Statement of changes in beneficial ownership - SEC Form 4. David Hale currently serves as non-executive chairman of the board of Biocept [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at Biocept

Biocept reported the previous year's revenue of 10.73 M. Net Loss for the year was (25.45 M) with loss before overhead, payroll, taxes, and interest of (5.45 M).

	2018	2019	2020	2021 (projected)
Revenues USD	3.25 M	5.53 M	6.36 M	6.86 M
Revenues	3.25 M	5.53 M	6.36 M	6.86 M

Revenues USD Revenues

Will Biocept growth be reasonable after the rise?

Current market risk adjusted performance is at -0.73. Biocept shows above-average downside volatility for the selected time horizon. We advise investors to inspect Biocept further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Biocept future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Biocept's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Biocept's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Whereas many other companies under the diagnostics & research industry are still a bit expensive, Biocept may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Biocept valuation and our trade advice on Biocept is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biocept.

About Contributor

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Biocept. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC